IMR Press / EJGO / Volume 18 / Issue 3 / pii/1997142

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Prognostic factors in endometrial carcinoma: risk groups and adjuvant radiotherapy

Show Less
1 Department of Gynecology, Section of Gynecologic Oncology, Hospital Universitari “La Fe”, Valencia, Spain
2 Department of Computer Sciences, Universitat Jaume I, Castellon, Spain
Eur. J. Gynaecol. Oncol. 1997, 18(3), 164–170;
Published: 10 June 1997

Prognostic factors for disease-free survival in patients with endometrial carcinoma have been retrospectively assessed in 611 cases diagnosed, treated and followed at our institution between 1971 and 1990. Age, symptoms, comorbidity, FIGO clinical stage, and hysterometry, as well as size and location of the tumor, histologic type, FIGO grade, myometrial invasion, lympho-vascular inva­sion, and final surgical stage have all been evaluated by univariate and multivariate methods. A mathematical predictive model has been applied to define risk groups, and the applied adjuvant treatments have been evaluated according to these groups. One hundred and thirtyone patients were not treated primarily with surgey, and the actuarial 5 and 10-year diesase-free survival was 51.6% and 34.7% respectively. Only clinical stage (FIGO 1971) and modality of radiotherapy were significant prognostic factors. For the 480 patients treated primarily by surgery, independent prognostic factors for 5 and 10-year disease-free survival in multivariate analysis were extrauterine spread, absence of diagnostic comorbidity, FIGO grades 2-3, lympho-vascular invasion, age >65 years and cervical extension. Five and 10-year disease-free survival was 81.5% and 73.4% respectively. Three risk groups were obtained, whose survival was not affected by the adjuvant treatments applied.

Endometrial carcinoma
Prognostic factors
Risk groups
Adjuvant treatment
Back to top